Calquence shows long-term efficacy and tolerability in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca's Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up, according to long-term follow-up data from the ACE-LY-004 Phase II trial.
At a median follow up of 38.1 months, 55 patients (44%) either remained on treatment (24 patients) or continued to be followed for survival (31 patients).
The results, presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, also showed a consistent safety and tolerability profile for the drug in this setting, with with only 14 patients (11%) having discontinued treatment due to adverse events.
Read more: http://www.pharmatimes.com/news/calquence_shows_long-term_efficacy_and_tolerability_in_mcl_1359178
At a median follow up of 38.1 months, 55 patients (44%) either remained on treatment (24 patients) or continued to be followed for survival (31 patients).
The results, presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, also showed a consistent safety and tolerability profile for the drug in this setting, with with only 14 patients (11%) having discontinued treatment due to adverse events.
Read more: http://www.pharmatimes.com/news/calquence_shows_long-term_efficacy_and_tolerability_in_mcl_1359178
